Palliative Care in Castrate-Resistant Prostate Cancer
Authors:
- Michael W. RabowMRMichael W. Rabow
- Michael Xiang LeeMLMichael Xiang Lee
- 1 November 2012
- journal article
- review article
- Published by Elsevier in Urologic Clinics of North America
- Vol. 39 (4) , 491-503
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology CareJournal of Clinical Oncology, 2012
- Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung CancerNew England Journal of Medicine, 2010
- Multinational, Double-Blind, Phase III Study of Prednisone and Either Satraplatin or Placebo in Patients With Castrate-Refractory Prostate Cancer Progressing After Prior Chemotherapy: The SPARC TrialJournal of Clinical Oncology, 2009
- Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced CancerJAMA, 2009
- A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancerCancer, 2007
- Impact of a Palliative Care Service on In-Hospital Mortality in a Comprehensive Cancer CenterJournal of Palliative Medicine, 2006
- Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate CancerNew England Journal of Medicine, 2004
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Palliative Care Inpatient Service in a Comprehensive Cancer Center: Clinical and Financial OutcomesJournal of Clinical Oncology, 2004
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI: Journal of the National Cancer Institute, 2002